Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 10/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 8/20 | 0.42 |
| ▸ | ACP1 | P24666 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PTGFR | P43088 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6463604 | 1.00 | MCHR1 (0.42) | MCHR1ADRA2AACP1PKMNPY5R | |
| SCHEMBL6872384 | 0.90 | MCHR1 (0.46) | MCHR1ADRA2AACP1NPY5RMAPT | |
| SCHEMBL6872387 | 0.90 | MCHR1 (0.46) | MCHR1ADRA2AACP1NPY5RMAPT | |
| SCHEMBL6874657 | 0.90 | ACP1 (0.41) | MCHR1ADRA2AACP1PKMNPY5R | |
| SCHEMBL6874646 | 0.90 | ACP1 (0.41) | MCHR1ADRA2AACP1PKMNPY5R | |
| SCHEMBL6458568 | 0.88 | SMN1; SMN2 (0.43) | MCHR1ADRA2ASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL6460801 | 0.88 | SMN1; SMN2 (0.43) | MCHR1ADRA2ASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL6878446 | 0.88 | MCHR1 (0.53) | MCHR1ADRA2ANPY5R | |
| SCHEMBL6878454 | 0.88 | MCHR1 (0.53) | MCHR1ADRA2ANPY5R | |
| SCHEMBL6874252 | 0.87 | ALDH1A1 (0.52) | MCHR1ADRA2ASMN1; SMN2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | claimed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | MCHR1 2/4885ADRA2A 117/4885ACP1 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.